The Americas geographic operating segment is our largest operating segment. Below, I will explain more in-depth each of the previously listed segments. These additional product segments include Spine, Office-Based Technology, Craniomaxillofacial and Thoracic, and Dental. Along with the three geographic segments, they report revenue according to the product which is sold as well. In each of the company’s three segments, they offer a vast array of products. ZBH reports revenue to three distinct business segments, which include “Americas, EMEA, and Asia-Pacific”.
Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. We collaborate with healthcare professionals around the globe to advance the pace of innovation.
We design, manufacture and market orthopedic reconstructive products sports medicine, biologics, extremities and trauma products office-based technologies spine, craniomaxillofacial and thoracic products dental implants and related surgical products. I have also priced in about 13% downside risk, where the stock would be priced at $103. I have priced in 22% upside potential for ZBH, putting a price target at $145. The selloff has created a buying opportunity for investors looking to get into the healthcare space. Over the last 5 years, the largest selloffs the stock has seen is 15%-22% (these selloffs are over the course of 2-3 months, compared to the roughly 1-month selloff due to the COVID-19 pandemic). During the market selloff, the stock was down nearly 46% before beginning to track back up again. Based on “elective surgeries” being stalled at hospitals because of the COVID-19 pandemic, the company’s stock has been hit hard due to market irrationality. Zimmer Biomet Holdings (NYSE: ZBH) has roughly 22% upside potential from current trading levels ($118.71).
0 kommentar(er)
